Polaryx Therapeutics, Inc. (PLYX) company profile
Close on Nov 17, 2026Market cap $79.75MP/E –Yield –
About Polaryx Therapeutics
Pharmaceutical Preparations, SIC 2834
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops treatments for rare pediatric lysosomal storage disorders. Its therapeutic pipeline comprises oral small molecule candidates and gene therapies targeting underlying cellular dysfunction and neuroinflammation. The company's lead product candidate is PLX-200, a reformulated oral solution targeting neuronal ceroid lipofuscinosis subtypes CLN2 and CLN3, Krabbe disease, and Sandhoff disease. Other programs include PLX-300, a small molecule in preclinical evaluation, PLX-100, an oral combination therapy, and PLX-400, an early-stage gene therapy. The company operates in the lysosomal storage disorders segment, developing therapies primarily for pediatric patients diagnosed with fatal genetic metabolic conditions.
The company maintains its principal executive offices in Paramus, New Jersey, and operates as a Nevada corporation. Polaryx utilizes external partnerships and receives consulting support across development functions from a team of eleven specialists based at its controlling shareholder in Hong Kong.
Summary of the business section of Polaryx Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Polaryx Therapeutics, Inc.
- Founded
- 2014
- Headquarters
- Paramus, NJ
- Address
- 140 East Ridgewood Avenue, Suite 415, South Tower 07652
- Phone
- (201) 940-7236
- Website
- polaryx.com
- Employees
- 11, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- WY
- Fiscal year ends
- December 31
- Auditor
- GRANT THORNTON LLP, Edison, New Jersey
Stock & identifiers
- Ticker
- PLYX
- Exchange
- Nasdaq
- IPO date
- Feb 2, 2026
- Shares outstanding
- 50M, Jul 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2075320
- CUSIP
- 73110F100
- ISIN
- US73110F1003
- FIGI
- BBG01ZPFWW22
- Share class FIGI
- BBG01ZPFWWC1
- LEI
- 529900HOCSZB5SQ6D467
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Alex Keun Mo Yang | Chief Executive Officer, Director | – |
| G. Michael Landis | Chief Financial Officer, Director | 228,225 |
| Lisa Bollinger | Chief Medical Officer | 150,358 |
| Andrew John O | Chief Investment Officer | 471,808 |
| Partners Healthcare Ltd Mstone | Director | 25,633,249 |
| III Francis A. Braun | Director | – |
| Mitchel Berger | Director | – |
| Charles S. Ryan | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Total | vs. prior year |
|---|---|---|---|---|
| Alex Yang Chief Executive Officer | – | $792.00K | $792.00K | +37% |
| Lisa Bollinger Chief Medical Officer* | $62.50K | $420.00K | $482.50K | – |
| G. Michael Landis Chief Financial Officer | $46.67K | $264.00K | $310.67K | +257% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 2, 2026
- Securities offered
- 47,343,297
- Exchange
- Nasdaq
- First trading day
- Feb 2, 2026
- First-day close
- $35.00
- Lock-up ends (est.)
- Aug 1, 2026
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 2, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Jan 27, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?